Clinical Trial: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241416) titled 'A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer' on Nov. 17.

Brief Summary: This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Intervention: DRUG: Rezvilutamide Tablets

Rezvilutamide tablets, oral administration.

DRUG: Enzalutamide Soft Capsules

Enzalutamide soft capsules, oral administration.

Recruitment Status: NOT_YET_REC...